Read Today’s Newspaper
☰ Mobile Logo

Hikma signs exclusive licence agreement with Azanta for Nimoral

By JT | 23:09 February 25, 2015 |
Share Story

AMMAN – Amman-based Hikma Pharmaceuticals announced Wednesday the signing of an exclusive licence agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). According to a company statement, Nimoral is a hypoxic radiosensitiser to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programmes throughout the world. Under the terms of the agreement, Hikma will have the exclusive rights to register, manufacture, distribute and market Nimoral in 20 markets in the MENA region including Turkey, leveraging Hikma’s strong local presence and regulatory expertise, with over 1,800 sales and marketing reps across the region.

.col-lg-12.second .opinion-widget{border-top:1px solid #D0D0D0;} #widget_1623 .opinions-title {font-size:32px;}

{{articles_filter_1623_widget?.title}}

Opinion Author
{{ articles_filter_1623[0]?.author_name }}

{{ articles_filter_1623[0]?.title }}
Opinion Author
{{ articles_filter_1623[1]?.author_name }}

{{ articles_filter_1623[1]?.title }}
.epaper-separator{ height: 1px; width: 100%; background-color: #D0D0D0; margin: 15px 0; }

Today’s Paper

Today's Paper
.related-articles .layout-ratio{padding-bottom:55%;}
Related Articles
.alert-success { color :#A3656F ; } .alert-danger { color : red ; } .footer { font-family:Myriad Pro,Arial; }
The Jordan Times Logo

The Jordan Times is an independent English-language daily published by the Jordan Press Foundation since October 26, 1975. The Jordan Press Foundation is a shareholding company listed on the Amman Stock Exchange.

Join Our Newsletters

Sign up by email to receive news.

Camera Icon Read Today’s Newspaper

Copyright © 2025 The Jordan Times. All Rights Reserved.

document.addEventListener('DOMContentLoaded', function () { function validateEmail(email) { return /^[^\s@]+@[^\s@]+\.[^\s@]+$/.test(email); } function showModal(message,type) { const messageContainer = document.getElementById("messageContainerFooter"); messageContainer.textContent = message; messageContainer.className = `alert alert-${type} mt-3`; // Bootstrap alert styling messageContainer.classList.remove("d-none"); // Hide message after 5 seconds setTimeout(() => { messageContainer.classList.add("d-none"); }, 5000); } document.getElementById("emailFormFooter").addEventListener("submit", function(event) { event.preventDefault(); const emailInput = document.getElementById("emailFooter"); const email = emailInput.value.trim(); if (!validateEmail(email)) { showModal('Invalid email format','danger'); return; } const url = `/subscribeNewsletter?email=${encodeURIComponent(email)}`; fetch(url, { method: "GET", headers: { "Accept": "application/json" } }) .then(response => { if (!response.ok) { showModal("Error submitting email. Try again.",'danger'); } return response.json(); }) .then(data => { showModal(data.message,'success'); }) .catch(error => { showModal("Error submitting email. Try again.",'danger'); }); }); });